Intracranial hemorrhage, also known as brain bleed, is a type of stroke where bleeding occurs within the skull or brain tissue itself. Quick medical treatment is crucial, as the condition prevents oxygen from reaching brain cells and can lead to permanent damage or death.

Understanding Treatment Goals and Challenges

When bleeding occurs in or around the brain, the main goals of treatment focus on stopping the bleeding as quickly as possible, reducing pressure inside the skull, and preventing further damage to brain tissue. The brain relies on a constant supply of oxygen delivered through blood vessels, and when a vessel ruptures or leaks, blood accumulates and creates pressure that blocks oxygen delivery to vital brain cells. Within just three to four minutes without oxygen, brain cells begin to die, and unlike other cells in the body, these cannot regenerate or come back.^[1]

Treatment decisions depend heavily on several factors. The location of the bleed within the brain makes a significant difference—bleeding deep inside brain structures requires different approaches than bleeding on the surface. The size of the hemorrhage matters greatly, as larger bleeds create more pressure and cause more damage. The patient’s overall health condition, age, and how quickly they receive medical attention all influence which treatments doctors choose and how successful the outcome might be. Some people arrive at the hospital within minutes of symptom onset, while others may not recognize symptoms immediately, and this time difference can be critical.^[2]

Modern medicine offers several standard treatments that have been approved by medical societies and proven effective through years of clinical practice. At the same time, researchers continue investigating new approaches in clinical trials (organized research studies that test whether new treatments work safely and effectively). These experimental treatments aim to improve survival rates and reduce the lasting disabilities that often follow brain hemorrhages. Currently, intracranial hemorrhage accounts for approximately 8 to 13 percent of all strokes, yet it carries higher rates of death and disability than other stroke types, making the development of better treatments urgently important.^[4]

Standard Medical Treatment Approaches

The first priority when a patient arrives at the hospital with suspected intracranial hemorrhage involves stabilizing their basic body functions. Medical teams work rapidly to ensure the patient can breathe properly, that their heart is pumping effectively, and that blood pressure remains at safe levels. If a patient’s consciousness level has dropped significantly or they cannot protect their airway, doctors may need to insert a breathing tube through the mouth and into the windpipe—a procedure called endotracheal intubation. This ensures adequate oxygen reaches the lungs and prevents complications like inhaling stomach contents.^[13]

Blood pressure management represents one of the most critical aspects of treating intracranial hemorrhage. High blood pressure can worsen bleeding and expand the size of the hemorrhage, yet lowering blood pressure too aggressively might reduce blood flow to healthy brain tissue. Medical guidelines recommend specific blood pressure targets based on research evidence. For patients with spontaneous intracerebral hemorrhage and systolic blood pressure (the top number in a blood pressure reading) between 150 and 220 millimeters of mercury (mm Hg), doctors typically aim to lower it to below 140 mm Hg within the first hour, unless specific medical reasons make this unsafe.^[12]

Several classes of medications help achieve these blood pressure targets. Antihypertensive agents (drugs that lower blood pressure) work through different mechanisms—some relax blood vessel walls, others slow the heart rate, and some reduce the volume of fluid in blood vessels. The choice depends on how quickly pressure needs to drop and the patient’s other medical conditions. Doctors monitor blood pressure continuously during this critical period, making frequent adjustments to medications as needed.^[12]

When bleeding occurs in patients taking blood-thinning medications, reversing these drugs becomes urgently necessary. Many people take anticoagulants (medications that prevent blood clots) like warfarin for conditions such as irregular heartbeat or previous blood clots. While these medications serve important purposes in preventing strokes caused by blocked vessels, they worsen bleeding when hemorrhage occurs. Doctors can reverse warfarin’s effects using vitamin K injections along with prothrombin complex concentrates (PCCs)—concentrated forms of clotting factors that help blood coagulate normally again.^[11]

For patients taking newer anticoagulants called direct oral anticoagulants (DOACs), specific reversal agents may be available depending on which drug the patient takes. The timing of reversal treatment matters greatly—the sooner anticoagulation is reversed, the better the chances of stopping hemorrhage expansion. Patients with low platelet counts or other blood clotting disorders may receive platelet transfusions or other blood products to help their blood clot properly.^[12]

Managing pressure inside the skull represents another essential treatment component. When blood accumulates within the rigid skull, it creates pressure on brain tissue because there is limited room for expansion. This increased intracranial pressure (ICP) can damage brain cells and reduce blood flow to healthy areas. Simple measures include elevating the head of the bed to 30 degrees, which helps fluid drain from the brain more effectively. Keeping body temperature normal prevents additional brain stress, as fever increases brain metabolism and worsens outcomes. Doctors avoid giving fluids that could increase brain swelling—instead they use solutions that match the salt concentration in blood.^[9]

When intracranial pressure rises dangerously high, doctors may use osmotic diuretics—medications that draw fluid out of brain tissue into the bloodstream, where kidneys can eliminate it. Mannitol is one commonly used osmotic agent. It works by creating a concentration gradient that pulls water from swollen brain tissue. Another medication called hypertonic saline (concentrated salt solution) works similarly. Both require careful monitoring because they affect the body’s fluid and salt balance. Medical teams measure the pressure inside the skull directly in some cases by placing a small monitoring device through the skull, which helps guide treatment decisions.^[12]

Seizures occur in some patients with intracranial hemorrhage, particularly when bleeding involves the surface of the brain. Seizures increase brain metabolism and can worsen brain damage, so preventing them becomes important. However, using anti-seizure medications preventively (before any seizure occurs) remains controversial. Current guidelines suggest considering preventive anticonvulsants (seizure-preventing medications) mainly for patients with hemorrhage in the outer portions of the brain called lobes. Levetiracetam has become preferred over older medications like phenytoin because it causes fewer cognitive side effects while providing similar seizure control.^[12]

The duration of medical treatment extends beyond the initial emergency period. Patients typically remain in an intensive care unit or specialized stroke unit for several days to weeks, depending on hemorrhage size and complications. During this time, medical teams work to prevent additional problems. Blood clots in leg veins can develop when patients remain immobile, so compression devices that squeeze the legs periodically help blood circulate. Stomach ulcers can develop from stress, so acid-reducing medications protect the stomach lining. Early involvement of physical, occupational, and speech therapists helps patients begin recovery as soon as their condition stabilizes.^[13]

Possible side effects of medical treatments vary depending on which medications are used. Aggressive blood pressure lowering might cause dizziness, kidney problems, or inadequate blood flow to the brain in some patients. Osmotic agents can disrupt the body’s salt balance, potentially causing dehydration or abnormal sodium levels. Reversing anticoagulation eliminates protection against clot formation, temporarily increasing risk of strokes caused by blocked vessels. Anti-seizure medications can cause drowsiness, dizziness, and in rare cases, serious allergic reactions. Medical teams carefully weigh these risks against the benefits of treatment, monitoring patients closely for any complications.^[12]

Surgical Treatment Options

Surgery becomes necessary for certain types of intracranial hemorrhages, particularly when the blood collection is large, causing significant pressure, or when the bleeding location makes surgical removal beneficial. The decision to operate depends on multiple factors including the patient’s age, neurological condition, the size and location of the hemorrhage, and whether the patient is deteriorating despite medical treatment. Not all brain hemorrhages benefit from surgery—in fact, removing blood clots deep within certain brain structures can sometimes cause more harm than leaving them alone.^[10]

Traditional open surgical procedures involve removing a section of skull bone to access the brain—a procedure called craniotomy. The surgeon creates an opening large enough to visualize the hemorrhage directly, then carefully removes the accumulated blood. This approach allows complete evacuation of the clot and control of any ongoing bleeding. However, craniotomy is a major operation requiring general anesthesia and several hours in the operating room. Recovery takes considerable time, and the procedure itself carries risks including infection, additional bleeding, and damage to healthy brain tissue that must be moved aside to reach the hemorrhage.^[10]

A less invasive surgical option involves inserting a thin tube called a catheter through a small hole in the skull. The catheter is threaded through brain tissue to the hemorrhage site, where it can drain liquid blood and dissolve clots using special medications. This minimally invasive surgery approach causes less disruption to healthy brain tissue and may allow faster recovery. However, it works best for certain hemorrhage types and locations, and may not completely evacuate all clotted blood. Research continues examining whether minimally invasive approaches provide better outcomes than traditional surgery or medical management alone.^[3]

Another surgical intervention addresses fluid buildup in brain cavities. The brain produces a clear fluid called cerebrospinal fluid (CSF) that normally circulates through hollow spaces called ventricles before being reabsorbed. When hemorrhage occurs, blood can block the drainage pathways, causing fluid to accumulate and pressure to increase—a condition called hydrocephalus. Surgeons can place a drainage tube called an external ventricular drain (EVD) through the skull into a ventricle to remove excess fluid and reduce pressure. This relatively quick procedure can be life-saving when hydrocephalus develops.^[11]

The timing of surgical procedures matters significantly. Some hemorrhages require immediate surgery—within hours of symptom onset—particularly if patients show signs of severe pressure on the brain or rapidly declining consciousness. Other situations allow time for medical stabilization before surgery. Occasionally, patients initially managed with medications alone require later surgery if they deteriorate or develop complications like hydrocephalus. The medical team discusses surgery risks and potential benefits with families, though in life-threatening situations, decisions must happen quickly.^[10]

Recovery after surgery varies greatly among individuals. Some patients show improvement within days as pressure on the brain decreases and swelling resolves. Others face a longer, more difficult recovery process involving intensive rehabilitation. The brain tissue damaged before or during surgery cannot regenerate, potentially leaving lasting disabilities. Physical therapy helps patients regain strength and movement. Occupational therapy teaches new ways to perform daily activities. Speech therapy addresses communication and swallowing difficulties. This rehabilitation process often continues for months after leaving the hospital.^[9]

Promising Treatments Being Tested in Clinical Trials

Researchers worldwide are investigating new treatments that might improve outcomes for people with intracranial hemorrhage. These studies progress through careful phases, starting with small safety studies and advancing to larger trials comparing new treatments against standard care. Understanding these phases helps explain why promising experimental treatments may take years to become widely available, and why not every patient can access them immediately.^[9]

Phase I clinical trials focus primarily on safety. Researchers test a new drug or treatment approach in a small group of people—often healthy volunteers for drugs, or people with the condition for procedures—to determine what doses are safe, how the body processes the drug, and what side effects occur. These early-stage trials help researchers understand whether it makes sense to continue studying the treatment. For intracranial hemorrhage, Phase I studies might test new medications that promote blood clotting, new surgical devices, or innovative ways to protect brain cells from damage.

Phase II clinical trials expand to larger groups of patients to assess whether the treatment actually works. Researchers measure specific outcomes—for brain hemorrhage, this might include whether a drug reduces the growth of hemorrhages, decreases pressure in the skull, or improves neurological function. Phase II studies also continue gathering safety information. These trials typically include carefully selected patients who meet specific criteria regarding hemorrhage size, location, and timing. Results from Phase II trials determine whether a treatment shows enough promise to justify the large expense and effort of Phase III trials.^[9]

One particularly well-studied experimental approach involves using recombinant activated factor VII (rFVIIa), a laboratory-manufactured version of a natural clotting protein. The idea behind this treatment is straightforward: if given very early after hemorrhage begins, this powerful clotting factor might stop bleeding quickly and prevent the hemorrhage from expanding. Early studies showed that patients receiving rFVIIa within four hours of symptom onset had less hemorrhage growth compared to patients receiving placebo (inactive treatment). The medication appeared to work through its effects on blood vessel walls and clotting mechanisms at the bleeding site.^[12]

However, subsequent larger Phase III trials revealed important limitations. While rFVIIa did reduce hemorrhage expansion as expected, this did not translate into better functional outcomes for patients. Treated patients did not have significantly better recovery or reduced disability compared to those receiving standard treatment. Additionally, rFVIIa increased the risk of thromboembolic events—dangerous blood clots forming in vessels throughout the body, potentially causing heart attacks or strokes from blocked arteries. This example illustrates why promising Phase II results do not always lead to approved treatments—the medication must improve meaningful outcomes for patients without causing excessive harm.^[12]

Researchers continue exploring other hemostatic therapies—treatments designed to stop bleeding. Studies have examined whether giving specific blood products, clotting factor concentrates, or medications that strengthen blood vessel walls might reduce hemorrhage expansion and improve outcomes. Some trials test whether existing medications approved for other bleeding conditions might help brain hemorrhage patients. Others investigate entirely new molecules designed specifically to address the bleeding mechanisms in brain hemorrhages.^[9]

Another research direction focuses on minimally invasive surgical approaches and new devices. One trial examined using very small surgical tools and specialized techniques to remove hemorrhages through tiny incisions, potentially reducing damage to healthy brain tissue compared to traditional craniotomy. Other studies test catheter-based systems that can both drain blood and deliver clot-dissolving medications directly into the hemorrhage. Some research centers investigate using specialized endoscopes (narrow tubes with cameras and instruments) to visualize and evacuate hemorrhages through smaller openings.^[9]

Neuroprotective agents—medications designed to protect brain cells from damage—represent another major research area. When hemorrhage occurs, the blood itself is toxic to brain tissue, and the pressure created causes additional injury. Various mechanisms contribute to this damage: inflammation develops, abnormal chemical reactions occur, and cells die through processes that continue for days after the initial bleeding. Researchers are testing medications that might interrupt these damaging processes, potentially salvaging brain tissue that would otherwise die.^[9]

Some neuroprotective approaches target specific molecules involved in brain injury. For example, researchers study drugs that reduce inflammation around hemorrhages, medications that prevent calcium from entering cells in harmful ways, and substances that neutralize damaging chemical reactions involving oxygen. While some of these approaches showed promise in laboratory studies with animals, translating this success to human patients has proven challenging. Human brain hemorrhages are more complex than laboratory models, and factors like patient age, other medical conditions, and treatment delays affect outcomes in ways difficult to replicate in research settings.

Phase III clinical trials represent the final major research stage before a treatment can receive regulatory approval. These large studies compare the new treatment directly against current standard care in hundreds or thousands of patients. Researchers measure important outcomes like survival, functional independence, and quality of life months after hemorrhage. Phase III trials happen at multiple medical centers—sometimes in several countries—to ensure results apply broadly to different patient populations. Because intracranial hemorrhage is relatively uncommon compared to other strokes, recruiting enough participants for Phase III trials takes considerable time.^[9]

Currently, several Phase II and Phase III studies are enrolling patients with intracranial hemorrhage at medical centers in the United States, Canada, Europe, and other regions. Each trial has specific eligibility requirements regarding patient age, hemorrhage size and location, time since symptom onset, and other medical factors. Patients interested in participating in clinical trials should discuss this option with their medical team. Doctors can search clinical trial databases to identify relevant studies and determine whether a patient might qualify.

Phase IV studies occur after a treatment receives approval, monitoring long-term safety and effectiveness in real-world practice. These studies help identify rare side effects that might not appear in smaller trials, determine whether the treatment works as well in routine practice as in carefully controlled research settings, and identify which patient subgroups benefit most. For intracranial hemorrhage treatments, Phase IV research might follow thousands of patients over years to fully understand benefits and risks.^[9]

Most Common Treatment Methods

• Blood Pressure Management
  • Rapid lowering of elevated blood pressure to prevent hemorrhage expansion, typically targeting systolic pressure below 140 mm Hg
  • Use of intravenous antihypertensive medications that allow precise, quick adjustments
  • Continuous blood pressure monitoring to avoid excessive lowering that could reduce brain blood flow
• Reversal of Anticoagulation
  • Administration of vitamin K and prothrombin complex concentrates to reverse warfarin effects
  • Use of specific reversal agents for direct oral anticoagulants when available
  • Platelet transfusions for patients taking antiplatelet medications or with low platelet counts
• Intracranial Pressure Management
  • Head of bed elevation to 30 degrees to promote fluid drainage from the brain
  • Osmotic diuretics like mannitol or hypertonic saline to reduce brain swelling
  • Direct intracranial pressure monitoring through devices placed in the skull
  • Surgical drainage of accumulated fluid when hydrocephalus develops
• Surgical Interventions
  • Traditional craniotomy for direct removal of large hemorrhages in accessible locations
  • Minimally invasive catheter-based drainage of blood with or without clot-dissolving medications
  • External ventricular drain placement to remove excess cerebrospinal fluid
  • Emergency surgery for rapidly deteriorating patients with life-threatening pressure
• Seizure Prevention
  • Selective use of anticonvulsant medications, particularly for lobar hemorrhages
  • Preference for levetiracetam over older medications due to fewer cognitive side effects
  • Continuous monitoring for seizure activity in high-risk patients
• Supportive Care
  • Airway protection with endotracheal intubation when consciousness level drops
  • Temperature control to prevent fever, which worsens brain injury
  • Prevention of deep vein thrombosis using compression devices
  • Gastric acid suppression to prevent stress ulcers
  • Early initiation of rehabilitation therapies once condition stabilizes
• Experimental Treatments in Clinical Trials
  • Hemostatic agents like recombinant activated factor VII tested for reducing hemorrhage expansion
  • Advanced minimally invasive surgical techniques and devices
  • Neuroprotective medications targeting inflammation and cellular damage mechanisms
  • Novel approaches to promote brain tissue recovery and reduce long-term disability